Valuation: Sensorion

Market Cap 151M 174M 141M 129M 242M 16.59B 246M 1.65B 648M 8.3B 653M 639M 27.64B P/E 2026 *
-39x
P/E 2027 * -6.5x
Enterprise Value 18.56M 21.43M 17.34M 15.85M 29.87M 2.04B 30.34M 203M 79.81M 1.02B 80.48M 78.73M 3.41B EV / Sales 2026 *
0.85x
EV / Sales 2027 * 23.5x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.84%
1 week+4.62%
Current month+4.62%
1 month+16.08%
3 months-31.40%
6 months-6.74%
Current year-14.14%
1 week 0.24
Extreme 0.238
0.25
1 month 0.21
Extreme 0.208
0.26
Current year 0.19
Extreme 0.1902
0.65
1 year 0.19
Extreme 0.1902
0.65
3 years 0.12
Extreme 0.121
0.98
5 years 0.12
Extreme 0.121
2.24
10 years 0.12
Extreme 0.121
2.89
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%+4.62% - - 172M
+1.29%+3.09%+6.43%+18.53% 49.47B
+0.89%+10.37%+491.34%+598.75% 43.97B
+3.08%+13.60%+24.57%+78.98% 39.6B
+1.38%+2.97%+34.54%+10.66% 39.29B
+0.85%+7.66%+21.22%+48.78% 32.43B
+0.08%+4.80% - - 16.84B
+1.99%+4.39%+38.70%+126.93% 16.49B
+0.34%+2.76%+5.39%+20.43% 14.01B
+3.56%+19.13%+86.23%+28.36% 12.77B
Average +1.53%+7.32%+88.55%+116.43% 29.43B
Weighted average by Cap. +1.48%+7.06%+107.88%+141.57%

Financials

2026 *2027 *
Net sales 21.86M 25.25M 20.43M 18.67M 35.19M 2.41B 35.74M 240M 94.01M 1.2B 94.81M 92.74M 4.01B 6.4M 7.39M 5.98M 5.46M 10.29M 705M 10.46M 70.09M 27.5M 352M 27.74M 27.13M 1.17B
Net income -237K -273K -221K -202K -381K -26.07M -387K -2.59M -1.02M -13.04M -1.03M -1M -43.44M -36.12M -41.72M -33.76M -30.86M -58.15M -3.98B -59.06M -396M -155M -1.99B -157M -153M -6.63B
Net Debt -132M -152M -123M -113M -212M -14.54B -216M -1.45B -568M -7.28B -573M -560M -24.23B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change
10/08/26 €0.2490 +1.84%
07/08/26 €0.2445 -3.36%
06/08/26 €0.2530 +1.40%
05/08/26 €0.2495 +4.83%
04/08/26 €0.2380 -3.45%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2925EUR
Average target price
1.138EUR
Spread / Average Target
+288.89%

Quarterly revenue - Rate of surprise